Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 Telatinib plus chemotherapy in first-line advanced gastric cancer
2009-010730-21Phase 2Completed
- Sponsor
- ACT Biotech Inc
- Start
- Apr 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of telatinib in gastric cancer (GC), sponsored by ACT Biotech Inc. Primary endpoint: Progression-free survival. Started Apr 2009; status: completed.
02
Drugs
telatinib
03
Conditions
gastric cancer (GC)
Beyond the preview
Go deeper on 2009-010730-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-010730-21.